GlaxoSmithKline Q2 net profit up 10.83%
- If Pakistan has sympathy for Kashmiri youth, they shouldn’t provoke them to attack army camps: Mehbooba Mufti
- Dhaka cafe attack mastermind, 2 others killed in police encounter
- Rio 2016 review: What they did at home, what in Olympics
- Buzz of change in Maldives, Mohammed Nasheed flies secretly to Lanka
- Kashmir: Police constable shot dead by terrorists
Drug firm GlaxoSmithKline Pharmaceuticals today reported a 10.83 per cent increase in net profit to Rs 163.52 crore for the quarter ended June 30, 2012, on robust growth across all business verticals.
The company had posted a net profit of Rs 147.54 crore for the corresponding period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a statement.
Total income of the company rose to Rs 661.86 crore for the quarter under consideration from Rs 573.85 crore reported in the year-ago period.
"The growth in net sales was 16 per cent and profit after tax and before exceptional items was 12 per cent. The core Pharmaceuticals business grew by 16.3 per cent for the quarter," the company said.
Commenting on the results GlaxoSmithKline Pharmaceuticals Managing Director Hasit B Joshipura said: "Growth for the quarter was market competitive, with all the segments delivering strong growth."
During the second quarter of this fiscal, the company also launched Uricostat for gout treatment. The company expanded its oncology portfolio by launching Hycamtin TM to fulfil unmet needs for patients with advance cancers and relapsed small cell lung cancer (SCLC), GlaxoSmithKline said.
- Dalits are angry about the hollowness of the current hyper-nationalism
- Atal Bihari Vajpayee’s slogan of 'insaniyat, Kashmiriat' has no meaning today
- Kejriwal’s attention is fixed on winning the Centre rather than making mohallas run better
- Inside Track: Turf tussle
- In Kashmir, so-called solutions are riddled with contradictions and divisions
- Why personal, social and political self-identification of Dalits must count more than legal nomenclature.